How Many People Have Taken Ozempic: Unpacking the GLP-1 Phenomenon and Personalized Weight Management

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide and tirzepatide have become household names in weight management, with clinical studies showing that approximately 15-20% of U.S. adults have either used or considered GLP-1 therapy. Behind this surge lies a straightforward principle: these medications help regulate appetite and blood sugar, making weight loss more achievable. Yet individual responses vary dramatically, which is why PlexusDx focuses on matching each patient with the medication and dose that fits their unique body chemistry.

The Rising Demand for GLP-1 Weight Loss Treatment

Global interest in GLP-1 therapy has grown exponentially over the past three years. Pharmacy data indicates that millions of prescriptions have been filled in the United States alone, with demand continuing to accelerate as more people learn about weight loss outcomes. This popularity reflects both the clinical effectiveness demonstrated in major trials and the growing recognition that weight management requires medical-grade support for many individuals.

Insurance coverage limitations and supply chain challenges have created barriers to access for many patients seeking GLP-1 therapy. PlexusDx addresses this gap by offering compounded semaglutide and tirzepatide through licensed 503A compounding pharmacies, serving all 50 states without requiring insurance or membership fees. This approach ensures that cost and logistics no longer prevent qualified individuals from accessing these proven medications.

Understanding GLP-1 Medication Options and Mechanisms

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that signals fullness to the brain and slows stomach emptying. Semaglutide and tirzepatide are the two most commonly prescribed compounds in this class, with tirzepatide also activating GIP receptors for a dual mechanism of action. Both medications improve fasting blood sugar, reduce cravings, and promote sustainable weight loss when combined with lifestyle modifications.

PlexusDx offers multiple delivery methods and formulations to match patient preferences and tolerability. Injection options include compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan and compounded tirzepatide at $289/mo month-to-month, or from $249/mo on the 6-month plan, while oral semaglutide is $289/mo month-to-month, or from $249/mo on the 6-month plan and oral tirzepatide at $349/mo (or $279/mo on the 6-month plan). The GLP-Squared Injection, a dual-compound option combining semaglutide and tirzepatide, is $289/mo month-to-monthnth for patients seeking enhanced efficacy. Your dose may need to go up. Your price won't.

Why Genetic Testing Improves GLP-1 Treatment Outcomes

Not every patient responds identically to GLP-1 therapy, and genetics play a significant role in medication efficacy and side effect tolerance. Key genetic variants in the GIPR, FTO, and MC4R genes influence how your body processes appetite signals and metabolizes these compounds. PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways across 49 peptides, providing 150+ genetic insights that guide personalized medication selection and dosing strategies.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Comparing Compounded GLP-1 to Commercial Alternatives

Commercial semaglutide and tirzepatide products face manufacturing constraints that drive up costs and limit availability. Compounded medications from licensed 503A pharmacies offer equivalent active ingredients at lower price points while maintaining rigorous quality standards. PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B—ensuring pharmaceutical-grade preparation tailored to individual patient needs.

Cost and accessibility remain critical considerations for patients committing to long-term weight management. PlexusDx medications are HSA/FSA eligible, require no insurance approval, and come with no hidden membership fees. Monthly pricing remains flat regardless of dose adjustments, so as your treatment progresses and your dose increases, your out-of-pocket expense stays predictable. This transparent pricing model makes sustained GLP-1 therapy financially sustainable for more patients.

Building a Sustainable Weight Loss Plan with Personalized Peptide Science

Medication alone does not guarantee lasting weight loss. The most successful outcomes combine GLP-1 therapy with consistent nutrition habits, regular physical activity, and behavioral support. PlexusDx guides patients through this comprehensive approach by describing the pathway-level variants involved.

Starting with the Microdose GLP-1 Protocol at $129/month allows patients to assess tolerability before committing to higher-dose semaglutide or tirzepatide. Once you've completed one month of treatment, adding the Precision Peptide Genetic Test ($298) reveals which peptide pathways drive your appetite, satiety, and metabolism, informing whether you'll benefit most from oral therapy, injectable therapy, or a dual-compound approach. This data-driven strategy maximizes both efficacy and patient satisfaction.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Precision Peptide Genetic Test is $298. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How many people have actually used Ozempic or similar GLP-1 medications?

Approximately 15-20% of U.S. adults have either used or considered GLP-1 therapy, with millions of prescriptions filled annually. Global demand continues rising as clinical evidence of weight loss and metabolic benefits spreads. PlexusDx serves this growing population by providing accessible compounded alternatives to commercial products through licensed 503A pharmacies across all 50 states.

What is the difference between semaglutide and tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx compounded GLP-1 more affordable than brand-name products?

Compounded medications from licensed 503A pharmacies bypass manufacturing and brand-marketing costs, allowing PlexusDx to offer compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan and tirzepatide at $289/month without insurance. All pricing is flat per compound across commitment tiers, meaning your dose can increase without increasing your monthly cost.

Are there side effects with GLP-1 therapy, and how can genetic testing help?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What does the Precision Peptide Genetic Test reveal about my treatment?

The $298 test maps 14 metabolic pathways and 49 peptides to generate 150+ genetic insights specific to appetite regulation, satiety signaling, and GLP-1 receptor responsiveness. Results guide whether you'll respond best to semaglutide, tirzepatide, a dual-compound approach, or PlexusDx's Microdose protocol, personalizing your entire weight loss strategy.

Related Reading

• Glp 1 For Losing Weight
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.